J. Rasmussen

发表

Efficacy of short and long-term venlafaxine ER treatment on somatic and psychic symptoms of GAD

C. White, P. Meoni, D. Hackett, 2000, European Neuropsychopharmacology.

A 24‐week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression

S. Montgomery, P. Tanghøj, J. Rasmussen, 1993, International clinical psychopharmacology.

Professional attitudes in the UK towards neuroleptic maintenance therapy in schizophrenia: The problem of inadequate prophylaxis

D. A. Johnson, J. Rasmussen, 1997 .

Drug treatments for schizophrenia - past, present and future.

J. Rasmussen, 1997, International journal of psychiatry in clinical practice.

A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

S. Kennedy, S. Rizvi, Kari A Fulton, 2008, Journal of clinical psychopharmacology.

Paroxetine and fluoxetine on food intake in rats and effect of paroxetine on body weight in depressed patients

A. M. Johnson, B. Stewart, J. Rasmussen, 1991, European Neuropsychopharmacology.

Use and misuse: Antidepressants in general practice.

N. Kosky, J. Rasmussen, 1999, International journal of psychiatry in clinical practice.

Dose Response Relationship of Citalopram 20 mg, Citalopram 40 mg and Placebo in the Treatment of Moderate and Severe Depression

S. Montgomery, K. Lyby, J. Rasmussen, 1992 .

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.

S. Montgomery, J. Rasmussen, 1992 .

Group therapy with OCD – development and outcome of diagnosis specific treatment of patients with OCD in groups

E. L. Mortensen, M. Fenger, M. Lau, 2010 .

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression

S. Montgomery, J. Rasmussen, 1992, European Neuropsychopharmacology.